Source: Pharmabiz

Cidara: Cidara begins patient dosing in phase 3 ReSPECT trial of rezafungin for prevention of invasive fungal disease in patients undergoing allogeneic BMT

Cidara Therapeutics, a biotechnology company, announced that the first patient has been dosed in its ReSPECT pivotal phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Jeffrey Stein's photo - President & CEO of Cidara

President & CEO

Jeffrey Stein

CEO Approval Rating

90/100

Cidara develops and commercializes novel anti-infectives and immunotherapies for the treatment of fungal infections. Read more